EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...
Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...
A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...
Earlier this week, Krystal Biotech reported positive interim data from the highest-dose cohort of its Phase 1 CORAL-1 trial, ...
With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...
The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...
Positive interim safety results from the first two dose escalation cohorts, referred to as Cohorts 1 and 2, were reported in 4Q 2024. Today’s update is focused on safety and molecular findings from ...
Tsingke Biotech's booth at the PEGS Summit attracted attention from global biopharma professionals, with many visitors engaging in discussions and companies exploring potential collaborations. This ...
Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding, bringing its total raised to $30 million. The round was led by Bessemer ...
Summit Therapeutics has generated plenty of buzz in the biotech industry over the past two years. That's because the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback